Non-hormonal male contraceptive implant lasts at least two years in trials | Medical research
Non -hormonal male contraceptives have been shown in experiments for at least two years.
Contraceptive methods, known as Adam, are soluble hydrogen in water that is planted in sperm channels, which prevents sperm from mixing with semen.
The company behind the product, Contraline, says the approach provides an alternative to convenience and cells, with a hydrogen designer to break the body after a specific period of time, and restore fertility.
Contraline issued details of its clinical experience in the first stage, and revealed that Adam could successfully obscure the launch of sperm for 24 months, with no sperm in the semen of the participants who have so far reached this time point in the experiment. In addition, he said no serious negative events have been recorded.
“This is really exciting because our goal since the first day was to create male contraceptives for two years-and this is what demand for two years or temporary or metaphorically required. We have the first data to show that this is possible.”
Eisenfrats said that the 25 participants in the clinical experiment have joined different points in time, with the expectation of more results. “It is a wonderful evidence of the concept,” he added ..
Eisenfrats said that the transplant was inserted into less gas procedures that took about 10 minutes and used a local anesthetic, which means that the patient has been awake.
Adam is not the first male contraceptive contraceptive in development that works by preventing sperm channels (deferred), although Eisenrats said that some other transplants used materials that did not collapse in the body. He said that there was no little data to show fertility that was restored after removing it, while there were also concerns that could cause such implants to be scarred in VAS supporters and lead to permanent sterilization.
The results of the clinical experience of Adam have not been published in the Journal of Laysee and not include data on the ability to transplant. However, Eisenrats said that hydrogel had a predictive age and has been proven that it has been disrupted over time in animal experiments, with less doses in men revealing a shorter period than effectiveness.
“How to think about this is like a IUD [intrauterine device] For men, Eisenfarz said, adding that after a period of two years, men can decide whether to get another cultivation. The team works to enable “reflection on request.” Eisenrats said that sperm tests can be used by men at home to verify whether the contraceptive methods are still effective.
Contraline said it is expected to start a clinical trial in the second stage in Australia later this year, which included 30 to 50 participants.
Professor Richard Anderson, a hormonal contraceptive expert at Edinburgh University, welcomed the results. “It is impressive that this seems to be something already working, which is great,” he said.
“We now have hormonal and non -hormonal methods in advanced clinical development, which is much better than we had previously in terms of getting something on the market for men to really use it.”
But Anderson and Professor John Awatley, from Washington State University, said at the present time no data has been released that shows Adam’s cultivation, and did not remain from the time when one transplant continued.
Anderson also said that it had not yet been proven that the transplant could be removed, while Awatley said that the long -term repercussions of the prohibition of VAS indicators were not known.
Overly said that although Adam’s transplant may be a strong option to prevent pregnancy for men, absorption may be limited. He said: “Given the choice of birth control pills, correction, injection, or surgery, I think most men will choose birth control pills or correction on surgery.”
